BioSpace News Archive

ConvenientMD—New England’s leading provider of urgent care and walk-in medical services is excited to announce the opening of a new clinic this July in Bellingham, MA, located at 245 Hartford Ave.

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited (“Takeda” or the “Company”) (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The Pancreatic Cancer Action Network (PanCAN) today announced the recipients of its 2019 research grants.

Ernst & Young (EY) honored Nephron Pharmaceuticals President and CEO Lou Kennedy as Health Care Entrepreneur of the Year for the Southeast on Thursday during a gala at the Coca-Cola Roxy in Atlanta.

Fresenius Kabi USA is voluntarily recalling the Volumat MC Agilia Volumetric Infusion Pump and Vigilant Drug’Lib to address software anomalies and to upgrade a “Keep Vein Open (KVO), End of Infusion” alarm.

This week, 13-year-old Hope Dees of Land O’ Lakes, FL joined more than 50 other pediatric patients from across the nation on Capitol Hill to meet with their members of Congress to speak out on behalf of children with complex medical conditions.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 1 ordinary share per ADS to 15 ordinary shares per ADS.

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the efficacy and safety of intravenous (IV) sildenafil when added to inhaled nitric oxide (iNO) for the treatment of newborns with Persistent Pulmonary Hypertension (PPHN) did not meet its primary efficacy endpoint.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has completed the previously announced sale of its Anatomical Pathology business to PHC Holdings Corporation, a leading global healthcare company providing innovative solutions, for approximately $1.14 billion in cash.

AIT Bioscience, a bioanalytical contract research organization (CRO) that is a member of Indiana’s life sciences hub, is celebrating its 10-year anniversary.